Whole-Blood Testing for Diagnosis of Acute Zika Virus Infections in Routine Diagnostic Setting

Jolanda J.C. Voermans; Suzan D. Pas; Anne van der Linden; Corine GeurtsvanKessel; Marion Koopmans; Annemiek van der Eijk; Chantal B.E.M. Reusken

Disclosures

Emerging Infectious Diseases. 2019;25(7):1394-1396. 

In This Article

The Study

We compared Zika virus quantitative reverse transcription PCR (qRT-PCR) results for 249 EDTA–whole blood and EDTA–plasma pairs submitted for laboratory testing from 227 patients with suspected Zika virus infection during July 2016–May 2017. These patients were those with a Zika virus diagnostic request in this period from whom both plasma and whole blood could be collected. In line with previous observations in our laboratory,[14] the first day of illness was provided infrequently, in only 29 (12.8%) of the 227 patients.

Using a standard EDTA blood collection tube, we aliquoted 600 μL of whole blood before the centrifugation step (10 min at 2,400 × g) to collect plasma. We stored the samples at −80°C until use. For testing, we spiked the samples with an internal control and extracted total nucleic acids from a 500-μL sample in 100 μL of eluate using the MagNAPure 96 DNA and Viral NA large volume kit and Viral NA Universal LV 2.0 protocol (Roche, https://www.roche.com), according to the manufacturer's instructions. Extraction was followed by an ISO15189:2012-validated laboratory-developed Zika virus qRT-PCR, as described previously.[15] We confirmed all Zika virus RNA−positive samples using a commercial Zika virus qRT-PCR (Altona Diagnostics, http://www.altona-diagnostics.com), as described by the manufacturer.

We detected Zika virus RNA in 31 (12.4%) of 249 whole-blood samples and in 23 (74.2%) of the 31 corresponding plasma samples. The 31 positive whole-blood samples were collected from 31 individual patients. This comparison indicated that 8 additional Zika virus–positive patients would have been identified if whole blood had been used routinely instead of plasma (Figure). This finding represented a 34% increase in confirmed cases of Zika virus infection.

Figure.

Overview of results of Zika virus diagnostic testing on total sample sets for 8 Zika patients additionally confirmed with Zika virus infection on the basis of whole-blood qRT-PCR. IgG, Zika virus IgG ELISA; IgM, Zika virus IgM ELISA; qRT-PCR, quantitative reverse transcription PCR; +, positive; –, negative.

Standard practice in international guidelines on diagnostic algorithms for Zika virus is to combine molecular testing of plasma with molecular testing of urine, along with serology, to come to an accurate Zika virus diagnosis. However, confirmation of cases based on serology only is usually limited to expert Biosafety Level 3 laboratories being able to perform virus neutralization tests comparing Zika virus titers with titers of other flaviviruses.[12,13] In our center, we routinely perform qRT-PCR on plasma and urine while running ELISA IgM/IgG testing in parallel on corresponding serum samples, provided these samples are submitted by treating physicians. Preferably, ELISAs are performed on paired serum samples taken at least 2 weeks apart (acute and convalescent phases) to monitor titer changes. However, these paired samples are not always submitted; for example, in our study cohort a second sample was provided for only 11 (61.1%) of 18 patients who were seropositive by ELISA and RT-PCR negative in plasma in the initial sample.

To determine whether our routine Zika virus testing algorithm, in which whole blood is not a sample of choice, would have missed the 8 additional identified patients, we evaluated the Zika virus test results of the complete sample set submitted for these patients (Figure). We tested urine and plasma by qRT-PCR as described previously and tested serum by ELISA (Euroimmun, https://www.euroimmun.com) for the presence of Zika virus–specific IgM and IgG, as described by the manufacturer. For 3 of the 8 additional patients, Zika virus infection had already been confirmed on the basis of the presence of Zika virus RNA and IgM in an earlier plasma sample. For the remaining 5 patients, only a status of probable case was achieved without the whole-blood testing.[12] Two of these patients had a status of probable infection on the basis of the presence of Zika virus IgM and IgG in an earlier sample, but no PCR was performed. Seven patients had the status of a probable Zika virus infection on the basis of serology performed on a same-date serum sample, and 1 patient had the status of past infection because of the absence of IgM. Two patients had no evidence for a recent Zika virus infection on the basis of a later serum sample that tested negative for RNA IgM and positive for IgG. The semiquantitative Zika virus ELISA did not show significant titer changes between different collection dates (data not shown).

processing....